Table 1. Patient characteristics at baseline (n=220).
| Characteristic | N (%) |
|---|---|
| Age at aNSCLC diagnosis, median (IQR) | 70.0 (62.8–76.0) years |
| Gender | |
| Male | 99 (45.0) |
| Female | 121 (55.0) |
| ECOG PS | |
| 0/1 | 131 (59.5) |
| 2/3 | 89 (40.5) |
| CCI, median (IQR) | 1.0 (1.0–3.0) |
| Smoking status | |
| Current | 79 (35.9) |
| Former | 122 (55.5) |
| Never | 19 (8.6) |
| Histology | |
| Non-squamous | 175 (79.5) |
| Squamous | 45 (20.5) |
| aNSCLC at presentation | 181 (82.3) |
| EGFR mutation | 3 (1.4) |
| ALK rearrangement | 0 (0.0) |
| Liver metastases | 18 (8.2) |
| Brain metastases | 30 (13.6) |
| Radiotherapy anytime during pembrolizumab treatment | 36 (16.4) |
| Prior line of palliative systemic therapy | |
| 0 | 210 (95.5) |
| 1 | 10 (4.5) |
| BMI | |
| ≥25 kg/m2 | 96 (43.6) |
| <25 kg/m2 | 112 (50.9) |
| Unknown | 12 (5.5) |
| Baseline NLR, median (IQR) | 5.5 (3.3–8.9) |
| Baseline PLR, median (IQR) | 262.1 (175.6–411.9) |
aNSCLC, advanced non-small cell lung cancer; IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance status; CCI, Charlson comorbidity index; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; BMI, body mass index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio;